- Home
- IGMS vs SQNS Comparison
IGMS vs SQNS Comparison
Compare IGMS & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- SQNS
- Stock Information
- Founded
- IGMS 1993
- SQNS 2003
- Country
- IGMS United States
- SQNS France
- Employees
- IGMS N/A
- SQNS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- SQNS Semiconductors
- Sector
- IGMS Health Care
- SQNS Technology
- Exchange
- IGMS Nasdaq
- SQNS Nasdaq
- Market Cap
- IGMS 82.1M
- SQNS 85.7M
- IPO Year
- IGMS 2019
- SQNS 2011
- Fundamental
- Price
- IGMS $1.24
- SQNS $2.07
- Analyst Decision
- IGMS Hold
- SQNS Strong Buy
- Analyst Count
- IGMS 8
- SQNS 1
- Target Price
- IGMS $6.14
- SQNS $7.50
- AVG Volume (30 Days)
- IGMS 198.4K
- SQNS 71.6K
- Earning Date
- IGMS 03-06-2025
- SQNS 02-11-2025
- Dividend Yield
- IGMS N/A
- SQNS N/A
- EPS Growth
- IGMS N/A
- SQNS N/A
- EPS
- IGMS N/A
- SQNS 2.00
- Revenue
- IGMS $2,679,000.00
- SQNS $36,762,000.00
- Revenue This Year
- IGMS $134.71
- SQNS N/A
- Revenue Next Year
- IGMS $74.27
- SQNS $95.51
- P/E Ratio
- IGMS N/A
- SQNS $1.08
- Revenue Growth
- IGMS 25.77
- SQNS 9.36
- 52 Week Low
- IGMS $1.15
- SQNS $0.85
- 52 Week High
- IGMS $22.50
- SQNS $4.28
- Technical
- Relative Strength Index (RSI)
- IGMS 37.38
- SQNS 31.20
- Support Level
- IGMS $1.17
- SQNS $2.10
- Resistance Level
- IGMS $1.31
- SQNS $2.49
- Average True Range (ATR)
- IGMS 0.09
- SQNS 0.15
- MACD
- IGMS 0.05
- SQNS 0.01
- Stochastic Oscillator
- IGMS 32.14
- SQNS 10.66
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.